^
Association details:
| Biomarker: | BCR-ABL1 T315I |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) + GMX1778 (Nicotinamide phosphoribosyltransferase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The Pivotal Role of Nicotinamide Phosphoribosyl Transferase in Chronic Myeloid Leukemia Cells Under Hypoxic Condition
Published date:
11/04/2020
Excerpt:
...in vivoefficacies of one of ABL TKI, ponatinib and CHS828 were evaluated in a mouse xenograft model. Ponatinib and CHS828 inhibited the growth of T315I mutant Ba/F3 cellsin vivomore than the control vehicle. We also found that co-treatment with ponatinib and CHS828 increased mouse survival. Combination treatment with ponatinib and CHS828 was also well tolerated, with no animal deaths in the treated mice.
